Immune-Mediated Colitis.
CTLA-4
Immune checkpoint inhibitor
Immune-mediated colitis
Immune-related adverse events
PD-1
PD-L1
Journal
Current treatment options in gastroenterology
ISSN: 1092-8472
Titre abrégé: Curr Treat Options Gastroenterol
Pays: United States
ID NLM: 9815941
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
20
11
2019
medline:
20
11
2019
entrez:
20
11
2019
Statut:
ppublish
Résumé
This review addresses our current knowledge of immune-mediated colitis (IMC) and offers a practical guide to its management. Due to the similarity in clinical, endoscopic, and histologic findings between IMC and inflammatory bowel disease (IBD), gastroenterologists have tailored their approach to IMC management to that of IBD. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that augment the T-cell anti-tumor response of the immune system and have demonstrated their importance in the treatment of a wide range of malignancies. With the growing benefits of ICIs, there are immune-related adverse events (irAEs) that mirror many known autoimmune diseases. Diarrhea and IMC are the most common and severe irAEs noted. No standardized guidelines exist in the management of these irAEs.
Identifiants
pubmed: 31741212
doi: 10.1007/s11938-019-00263-0
pii: 10.1007/s11938-019-00263-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
506-523Références
Clin Cancer Res. 2017 Aug 15;23(16):4534-4539
pubmed: 28611199
J Immunother Cancer. 2018 Oct 11;6(1):103
pubmed: 30305177
Gastrointest Endosc. 2017 Nov;86(5):915-916
pubmed: 28478027
Curr Oncol. 2015 Aug;22(4):e320-2
pubmed: 26300683
Dig Dis Sci. 2010 May;55(5):1396-405
pubmed: 19507029
Clin Gastroenterol Hepatol. 2016 Jun;14(6):836-842
pubmed: 26748223
J Crohns Colitis. 2016 Apr;10(4):395-401
pubmed: 26783344
Front Oncol. 2017 Apr 03;7:56
pubmed: 28421161
J Immunother Cancer. 2019 Apr 2;7(1):93
pubmed: 30940209
Melanoma Res. 2015 Apr;25(2):178-9
pubmed: 25464388
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
Ann Oncol. 2013 Jul;24(7):1813-1821
pubmed: 23535954
J Immunother Cancer. 2018 May 11;6(1):37
pubmed: 29747688
J Clin Oncol. 2006 May 20;24(15):2283-9
pubmed: 16710025
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
J Clin Oncol. 2017 Dec 1;35(34):3815-3822
pubmed: 28915085
Mayo Clin Proc. 2013 Apr;88(4):414-7
pubmed: 23541015
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Can J Gastroenterol Hepatol. 2016;2016:2483261
pubmed: 27774443
Aliment Pharmacol Ther. 2015 Aug;42(4):406-17
pubmed: 26079306
PLoS One. 2016 Jul 29;11(7):e0160221
pubmed: 27472273
Ann Intern Med. 2012 Mar 6;156(5):350-9
pubmed: 22393130
Gut. 2017 May;66(5):839-851
pubmed: 26893500
J Natl Compr Canc Netw. 2018 May;16(5S):594-596
pubmed: 29784734
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Br J Cancer. 2016 May 10;114(10):1084-9
pubmed: 27124339
Clin Cancer Res. 2011 Feb 15;17(4):896-906
pubmed: 21106722
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
Nat Rev Drug Discov. 2016 Apr;15(4):235-47
pubmed: 26965203
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
Ann Oncol. 2017 Jun 1;28(6):1368-1379
pubmed: 28368458
Inflamm Bowel Dis. 2018 Jul 12;24(8):1695-1705
pubmed: 29718308
Cancer Immun. 2010 Nov 24;10:11
pubmed: 21090563
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
Nat Med. 2018 Dec;24(12):1804-1808
pubmed: 30420754
J Clin Oncol. 2017 Dec 1;35(34):3807-3814
pubmed: 28841387
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Ann Transl Med. 2016 Jul;4(14):261
pubmed: 27563648
Front Pharmacol. 2017 Feb 08;8:49
pubmed: 28228726
Oncoimmunology. 2017 Jul 5;6(10):e1344805
pubmed: 29123955
Biomed Rep. 2016 Oct;5(4):403-407
pubmed: 27699005
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
AJR Am J Roentgenol. 2013 May;200(5):W468-74
pubmed: 23718569
Front Immunol. 2017 Nov 15;8:1547
pubmed: 29230210
BMJ Case Rep. 2016 Aug 18;2016:
pubmed: 27539137
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Clin Cancer Res. 2008 May 15;14(10):3044-51
pubmed: 18483370
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
ESMO Open. 2018 Jan 13;3(1):e000278
pubmed: 29387476
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancer Immunol Immunother. 2017 May;66(5):581-592
pubmed: 28204866
Med Oncol. 2011 Dec;28(4):1140-4
pubmed: 20593249
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
J Clin Oncol. 2012 Jul 20;30(21):2691-7
pubmed: 22614989
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8
pubmed: 17982122
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Transl Lung Cancer Res. 2015 Oct;4(5):560-75
pubmed: 26629425